The Ancient Art of Looking, Feeling Oh So Much Younger

By Isabelle Piermattio

Face it, women of Asian descent often look so fabulously young. Could it be their diet? Supplements? Or, the manner in which they express emotion and facial expressions?

All of the above, says Dr. Ming Ming Molony, who also professes the use of acupressure and pressure to points for an au natural, truly affordable facelift.

Dr. Molony, recently released the DVD “The Ancient Art of the Acupressure Facelift,” shows the natural, super affordable way to a rejuvenating facelift, all for less than pennies a day.

The Chinese acupressure facelift is the natural way to achieve a youthful radiant appearance, increase circulation, reduce double chin, eye wrinkles, forehead wrinkles, jaw pain, stress, headaches and more. The program instructs how to use facial exercises and acupressure points to tone facial muscles, and soothe the skin.

“Looking younger naturally is possible with little effort, no surgery and no expensive topical creams,” says Ming Ming, a native of China. Ming practices Chinese medicine, acupuncture and acupressure in northeast Pennsylvania with her husband, author, speaker and Chinese medicine practitioner, Dr. David Molony, who in 2006, was the first ever Caucasian to earn the World Federation of Chinese Medicine Renji Award.

Both Drs. Ming Ming and Dr. David Molony are featured on the DVD. The Chinese Acupressure Facelift is available online.

For more information on the DVD please call (610) 266-6110 or visit the Amazon.com store.

Aqua Stealth Jacket with fashion forward Bucket Hat

Bethany Bunnell, founder and president of SunSafe, has been cutting a cool swathe of sun safe apparel since 1994, when as a young mother and designer, she was living in the Asian tropics, realizing the immediate need for sun safe clothing for her growing family.

“I knew that sunscreens alone would not provide enough coverage for my fair skinned children who wanted to be out on the beach all day,” recalls Bunnell. Today, 15 years after designing her first line of sun safe children’s clothing, Sun Safe has become a leader in sun safe apparel and sun safety for the entire family.

Beyond the stylish spins on fashionable sun safe clothing for men, women, children and infants, SunSafe works to help educate the public about sun safety sun exposure and skin cancer. The firm helped to create the first US standard in UV protection for fabrics, using a UPF transmission test to measure the amount of UVB and UVA rays blocked by the fabrics they employ.

Year round, SunSafe provides a cache of updated, fashion forward designs using lightweight fabrics that block 97.5 percent of the UVB and UVA rays transmitted by the sun.  Today, SunSafe marches on, with stylish spins on cool outdoorsy clothes for your entire brood. For more information, visit www.sunsafe.com or call 1-800-Sun-Safe.

Tina Cantelmi is a fashion and fitness writer who has contributed to pages of Women’s Wear Daily, Runner’s World, and Parenting Magazine.

Launch of Compassionate-Use Drug Opens New Avenue in Fight Against Cancer

By Randy Lieberman

If there was any hope for finding a cure for cancer, this may be it.

Cancer takes more than 600,000 lives in the United States each year, according to National Cancer Institute.

A new ray of hope to these victims is the announcement that Provectus Pharmaceuticals Inc. has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic drug for a broad spectrum of cancers, available for select cancer patients.

The development-stage oncology and dermatology bio-pharmaceutical company, Provectus will initially make the compassionate use program available for cancer indications that do not involve visceral organs and are not subject to enrollment in ongoing clinical trials. These indications include certain breast cancers, basal cell carcinoma, squamous cell carcinoma, certain head and neck cancers and melanoma.

PV-10 is a form of Rose Bengal that is injected directly into a tumor, and according to Dr. Agarwala, Principal Investigator for Provectus’ Phase 2 PV-10 trial site at St. Luke’s Hospital & Health Network in Bethlehem, PA, has shown a 60 percent efficacy rate with little, or no side effects.

Provectus has begun its compassionate program for PV-10 in certain Australian “Centers of Excellence,” including Sydney, Brisbane and Adelaide, and will expand it to the United States in coming months. The Australian program is under the guidelines of the Therapeutic Goods Administration’s Special Access Scheme.

The U.S. program on the other hand is expected to be under the FDA’s regulations covering Treatment Use of an investigational new drug. Compassionate use programs provide experimental therapeutics to patients prior to final FDA approval.

Provectus received orphan drug designation from the FDA for its melanoma indication in early January of 2007. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology.

Dr. Kelly McMasters, a preeminent physician and investigator who is a member of Provectus’ Board of Directors and head of its Scientific Advisory Board, will advise the Company on candidates for the program who might be safely helped by PV-10.

McMasters said, “The potential for PV-10 to successfully treat metastatic melanoma, which has already been shown in humans, warrants its further use for melanoma and for other life-threatening scenarios on a compassionate use basis.”

Provectus is currently completing its Phase 2 clinical trial of PV-10 as a therapy for metastatic melanoma and has completed Phase 1 clinical testing of PV-10 for the treatment of recurrent breast carcinoma.

“We decided to initiate this program as we have had a continuing large number of requests by physicians and patients to make PV-10 available on a compassionate basis,” said Craig Dees, Ph.D., CEO of Provectus.

“Preliminary analysis of interim Phase 2 results from our melanoma clinical trial suggests that we can safely provide PV-10 for treatment of selected cancer patients, and that the agent has potential to benefit some of these patients. Knowing this information, we believe the ethical choice is to make the drug available on a compassionate use basis.”

Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov.

Interested parties are encouraged to visit Provectus’ website, www.pvct.com, where details on the compassionate use program and additional information will be posted in the near future.

KNOXVILLE, TN (June 1, 2009) /PRNewswire/ — Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and caused selective tumor destruction in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled “Chemoablation of melanoma with intralesional rose bengal (PV-10),” in the General Poster Session.

Key interim data from the first 40 subjects in the Phase 2 study included:

• Objective response of PV-10 treated lesions was observed in 60% of subjects.
• Locoregional disease control of treated lesions was observed in 75% of subjects.
• Response of untreated bystander lesions was consistent with observations from Phase 1 testing.
• Interim safety data were comparable to Phase 1, with transient mild to moderate locoregional pain, vesicles, edema or swelling most common.

“These data provide us much encouragement as they continue to demonstrate how potentially safe and effective PV-10 is for the treatment of metastatic melanoma,” said Dr. Sanjiv Agarwala, Principal Investigator for Provectus’ Phase 2 PV-10 trial site at St. Luke’s Hospital & Health Network in Bethlehem, PA, who presented the abstract at ASCO. “Particularly positive is further evidence of the ‘bystander effect,’ which appears to induce the patient’s immune system to attack and shrink untreated tumors. Because melanoma often metastasizes in areas of the body that are difficult to treat, such as the head and neck, the ‘bystander effect’ could dramatically improve the prognosis for many patients. We are excited about these results and look forward to continued development of this therapy.”

Dr. Craig Dees, PhD, Chairman and Chief Executive Officer of Provectus said, “The progress we are making in the clinical trials of PV-10 helps pave the way for its possible future as a safe and effective therapy for metastatic melanoma patients. The results presented from the first 40 subjects in the Phase 2 trial bring us another step closer to helping the many thousands of individuals afflicted each year with this insidious disease, whose incidence is rising faster than any other cancer in the U.S. today.”

The American Cancer Society estimates that there are 120,000 patients in the United States with Stage III or Stage IV melanoma, and that 68,000 new cases will be reported in 2009. The World Health Organization reported that it expected 48,000 global deaths in 2008 alone from Stage III or Stage IV melanoma.